Kotsai Pharmaceutical

Kotsai Pharmaceutical is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to the development of next-generation small molecule precision medicines for oncology. The company’s research focus centers on targeting genetically defined subsets of cancers with high unmet medical needs, particularly those involving kinase mutations. Kotsai's lead product candidate, KS-101, is a selective inhibitor of EGFR and HER2 exon 20 insertion mutations, currently undergoing Phase 1/2 clinical evaluation for the treatment of advanced non-small cell lung cancer. The company leverages a structure-based drug design platform to optimize the potency and selectivity of its therapeutic candidates. Supported by prominent venture capital investors, Kotsai aims to overcome current treatment resistance mechanisms in solid tumors and provide more effective therapies for cancer patients.